BZ vs ZM vs MSFT vs RCUS

For growth investors, Kanzhun Limited (BZ) is the stronger pick with 23.

6% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Zoom Communications, Inc. (ZM) offers the better valuation at 17. 5x trailing P/E (18. 4x forward), making it the more compelling value choice. Analysts rate Kanzhun Limited (BZ) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zoom Communications, Inc.

(ZM) is the cheapest at 17. 5x versus Microsoft Corporation at 30. 9x. On forward P/E, Kanzhun Limited is actually cheaper at 1. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoom Communications, Inc. wins at 0. 82x versus Microsoft Corporation's 1. 35x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Microsoft Corporation (MSFT) delivered a total return of +72.

5%, compared to -63. 3% for Zoom Communications, Inc. (ZM). Over 10 years, the gap is even starker: MSFT returned +787. 7% versus BZ's -60. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Microsoft Corporation (MSFT) is the lower-risk stock at 0.

89β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 120% more volatile than MSFT relative to the S&P 500. On balance sheet safety, Zoom Communications, Inc. (ZM) carries a lower debt/equity ratio of 0% versus 33% for Microsoft Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kanzhun Limited (BZ) is pulling ahead at 23.

6% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Zoom Communications, Inc. grew EPS 92. 5% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zoom Communications, Inc.

(ZM) is the more profitable company, earning 39. 0% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 39. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MSFT leads at 45. 6% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoom Communications, Inc. (ZM) is the more undervalued stock at a PEG of 0. 82x versus Microsoft Corporation's 1. 35x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Kanzhun Limited (BZ) trades at 1. 7x forward P/E versus 25. 3x for Microsoft Corporation — 23. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BZ: 96. 6% to $28. 00.

In this comparison, MSFT (0.

8% yield) pays a dividend. BZ, ZM, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Microsoft Corporation (MSFT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

89), 0. 8% yield, +787. 7% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MSFT: +787. 7%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BZ (Industrials) and ZM (Technology) and MSFT (Technology) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BZ is a mid-cap high-growth stock; ZM is a mid-cap deep-value stock; MSFT is a mega-cap quality compounder stock; RCUS is a small-cap quality compounder stock. MSFT pays a dividend while BZ, ZM, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.